Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount

Novartis' Sandoz unit licensed U.S. rights to Adamis' Symjepi in July. (Novartis)

Only days after Teva launched its generic to Mylan’s EpiPen, Novartis’ Sandoz has released launch plans for its own epinephrine injector product. Sandoz’s Symjepi won FDA approval in September, and on Thursday the company said it will launch in early 2019 at a slight discount to options from Mylan and Teva. 

While Teva opted not to release its medication with a list-price discount compared with Mylan’s authorized generic, Sandoz is going with a 16% discount.

Sandoz’s two-pack will hit the market with a list price of $250, while Teva and Mylan injectors cost $300 for a two-pack.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Sandoz is “well underway to ensure appropriate supply of this life-saving medicine for healthcare professionals and patients in need of a new treatment option,” according to a Thursday release

RELATED: Look out, EpiPen. With Adamis deal, Novartis is gunning for your sales 

Adamis Pharmaceuticals developed Symjepi and licensed U.S. rights to the epinephrine injector to Sandoz in July. The product won FDA approval in September. 

Thursday's news follows Teva’s generic EpiPen launch late last month. That drugmaker suffered two years of regulatory delays and finally won approval in August. 

Earlier in the EpiPen saga, Mylan faced criticism for routine price hikes that took branded EpiPen’s price to more than $600 for a two-pack. Amid the controversy, the company said it would release an authorized generic, which now costs $300 for a two-pack.

Due to new competition and new scrutiny on its big-selling injector, EpiPen sales fell $655 million last year, Mylan disclosed.

Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.